The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.
about
History of clinical transplantationMicro and nanoparticle drug delivery systems for preventing allotransplant rejectionDoes tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 yearsReplicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugsA comprehensive review of immunosuppression used for liver transplantation.A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.Hepatic and intestinal transplantation at the University of Pittsburgh.Hepatic resection and transplantation for peripheral cholangiocarcinoma.Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.Should hepatomas be treated with hepatic resection or transplantation?Pregnancy after liver transplantation under tacrolimus.Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years.Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.The current status of hepatic transplantation at the University of PittsburghTacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntletTreatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantationThe mother lode of liver transplantation, with particular reference to our new journal.Weaning of immunosuppression in liver transplant recipients.Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantationIncidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferonUrgent revascularization of liver allografts after early hepatic artery thrombosis.Liver transplantation in the UK.Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) inductionTreatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.Pharmacotherapy of scleritis: current paradigms and future directions.Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation.Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.Nanotechnological Approaches to Immunosuppression and Tolerance Induction.What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.Low Serum Levels of (Dihydro-)Ceramides Reflect Liver Graft Dysfunction in a Real-World Cohort of Patients Post Liver Transplantation.
P2860
Q24596303-75A91BFF-6D36-4F42-A2BE-8FDF1CDEACC1Q28080720-BB81C654-4B00-4143-9621-5190D8F722DAQ28344317-9CF41DE0-F28E-419C-ABDE-1D45A1C77C73Q28362068-1A6AF07E-1980-48BC-89ED-83E6542925ECQ33602527-42F0A4DE-C2AC-492F-AA35-F41031433B86Q34187619-69CC92DC-6BDB-40CA-8177-C9CDC9774CD5Q34206468-770E07C6-8693-4D41-9152-ECCD7196A99AQ34219045-58FC8C91-F6A9-4F4B-892D-63F4A7DA6296Q34231590-269440D4-88AE-407A-A0DF-74EB89D5179EQ34281054-8D7B0108-1179-4EEC-A610-9AA5B832144DQ34287269-E1D54AB0-993D-4167-A922-D24EC80F91BFQ34287276-294D2423-0B07-43F5-952D-CC77A8A2DAD4Q34304992-E45823C3-9D0E-4495-9F0B-4B1E7EBD3CFEQ34330449-36821F41-C185-4271-9975-ABF35F27E71DQ34340969-B0D105D8-F879-4A25-B881-2AFFF7D47C88Q34346870-A069E407-0258-485E-B5BF-66D1A1841338Q34359339-CDC2DE8E-5EC8-431C-B5CF-F3E80ED8E66CQ34421352-EBD51ADF-965E-4FB9-A6B6-7EE4AA8E3711Q34421431-7FD472ED-6AA2-4039-99F3-11FB53F71214Q34423385-73CB2346-4443-411E-BA86-BC680F49361AQ34480368-4A1CE49F-0323-4948-ADF2-8EDD105403FFQ34512132-C1EF8715-4579-4703-BBD4-02468BE8F1E6Q35253580-ED65E693-2B74-465C-9EC2-EA77F5BE3146Q37208060-81A87C4A-66D9-4EAD-9144-DD1BB7734B71Q37355472-C00B7F51-BCD6-4F7C-AFDA-6FBB8ED640E5Q37466204-64001092-100C-4A82-AAE2-26DDAA1EF758Q42028499-CD4D54C8-7590-4616-A3C7-0679015F00CFQ42142894-7BCA7131-3A97-472C-8B9D-A219A6B14FFFQ50066247-0DCD81E0-7DA0-4EF4-A06E-198BD1F9A2D8Q54078474-14FAC3CC-7B62-4842-9A8B-85137E22CA34Q54963944-B27CF739-D5B1-4F83-A866-23A4F9C324E8
P2860
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@en
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@nl
type
label
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@en
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@nl
prefLabel
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@en
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@nl
P2093
P2860
P50
P1476
The Pittsburgh randomized tria ...... e for hepatic transplantation.
@en
P2093
P2860
P304
P577
1996-08-01T00:00:00Z